CLOs on the Move

Syneos Health

www.syneoshealth.com

 
"Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers` delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details
Karen Stringer
 VP, Assistant General Counsel, Deputy Chief Compliance Officer Profile
Kristen Galloway
 Vice President and Assistant General Counsel Profile
Kristen Greene
 Vice President and Assistant General Counsel Profile
Danielle Bello
 Counsel and Director Litigation, Risk and Claims Profile
Megan Isaacson
 Associate Director, Legal Operations Profile

Similar Companies

Nutra Manufacturing

Nutra Manufacturing, Inc is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

TB Alliance

TB Alliance is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gavis Pharmaceuticals

Gavis Pharmaceuticals is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Merz Pharmaceuticals

Merz Pharmaceuticals is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.